Management approaches include non-pharmacologic strategies, optimization of dry weight, dietary sodium restriction, dwell time adjustments, low-sodium dialysate, icodextrin use for improved ultrafiltration, and physical activity and pharmacologic therapies including ACE inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers, beta-blockers, diuretics, mineralocorticoid receptor antagonists (MRAs), and agents for resistant hypertension such as clonidine and moxonidine. This evidence concerns the gene NR3C2 and Hypertension resistant to conventional therapy.